Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on August 26, 2008
JNCI Journal of the National Cancer Institute 2008 100(17):1191; doi:10.1093/jnci/djn332
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/17/1191-b    most recent
djn332v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

MEMO TO THE MEDIA

Angiotensin Inhibitors and Receptor Blockers Linked to Lower Risk of Nonmelanoma Skin Cancer

The first 10% of the full text of this article appears below.

The use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was associated with a reduced risk of basal cell or squamous cell skin cancers in U.S. veterans, researchers report in the August 26 online issue of the Journal of . . . [Full Text of this Article]

Contact:

Citation:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Association of ACE Inhibitors and Angiotensin Receptor Blockers with Keratinocyte Cancer Prevention in the Randomized VATTC Trial
Jennifer B. Christian, Kate L. Lapane, Anne L. Hume, Charles B. Eaton, and Martin A. Weinstock
J Natl Cancer Inst 2008 100: 1223-1232. [Abstract] [Full Text] [PDF]